US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi NVO 2x Daily ETF

17.47

0.0000

Volume:33

Turnover:599.19

Market Cap:262.02K

PE:- -

High:17.47

Open:17.47

Low:17.47

Close:17.47

52wk High:27.19

52wk Low:17.37

Shares:15.00K

Float Shares:15.00K

Volume Ratio:3.12

T/O Rate:0.22%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Novo Nordisk’s CagriSema Trial Targets Painful Diabetic Nerve Damage

Novo Nordisk's Semaglutide Injection Gets Chinese Approval for MASH Treatment

MT Newswires Live

Novo Nordisk Advances Oral Semaglutide Trial in Obesity: What Investors Should Watch

Novo Nordisk A/S Series B Stock Falls Wednesday

Novo Nordisk Advances DKK 15 Billion Share Buyback, Holding 1% of Capital in Treasury Stock

Korean Equities Rally Drives Leveraged ETFs Higher, Top Performer Surges 9%

Novo Nordisk A/S Stock (NVO) Closed Down by 3.09% on Sep 8: Facts Behind the Movement

GLP1 Drugs Work for Kids, Says Novo Nordisk. They Could be Another Huge Market.

Update: US Equity Futures Mostly Lower as Traders Assess Rising Oil, Canadian Retaliatory Tariffs

MT Newswires Live

Plastic Surgery is Booming with Boomers. Here's How to Cash in on the Antiaging Craze.

Novo Nordisk Phase 3 Trial Meets Primary Endpoint for Child Obesity Drug

MT Newswires Live

Market Chatter: Novo Nordisk Halts Two More Ziltivekimab Trials

MT Newswires Live

The Inflammation Bet Unravels: Novo And Novartis Both Stumble In Cardiovascular

Bellwether Stocks Movement

Novo Nordisk (0QIU) Receives a Hold from Barclays

Novo Nordisk halts two trials testing ziltivekimab, Bloomberg reports

Yen advances to six-month high, chip stocks rise

Nicholas Reynolds / Bloomberg

Novo Nordisk announces STEP Young phase 3 trial met its primary endpoint

Novo Nordisk (NVO) Hit by Another Heart Drug Setback

Novo Nordisk A/S Series B Stock Flat Monday, Underperforms Market

Novo Nordisk Stock (NVO) Falls Despite Success in Children’s Weight-Loss Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/NVOC/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOC\",,,,,undefined,":{"symbol":"NVOC","market":"US","secType":"STK","nameCN":"Corgi NVO 2x Daily ETF","latestPrice":17.468,"timestamp":1789657129542,"preClose":17.468,"halted":0,"volume":33,"delay":0,"changeRate":0,"floatShares":15000,"shares":15000,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"09-17 11:18:45 EDT","open":17.468,"high":17.468,"low":17.468,"amount":599.19321,"amplitude":0,"askPrice":18.54,"askSize":500,"bidPrice":18.46,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"listingDate":1784001600000,"exchange":"CBOE","adjPreClose":17.468,"nav":18.17,"aum":272550,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":17.37,"preClose":17.468,"latestTime":"16:10 EDT","volume":4,"amount":69.872,"timestamp":1789589404369,"change":-0.098,"changeRate":-0.00561,"amplitude":0},"volumeRatio":3.123637},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOC\",,,,,undefined,":{"symbol":"NVOC","floatShares":15000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.123637,"shares":15000,"dividePrice":0,"high":17.468,"amplitude":0,"preClose":17.468,"low":17.468,"week52Low":17.37,"pbRate":"--","week52High":27.1863,"institutionHeld":0,"latestPrice":17.468,"eps":0,"divideRate":0,"volume":33,"delay":0,"ttmEps":0,"open":17.468,"prevYearClose":24.92,"prevWeekClose":18.6239,"prevMonthClose":20.8451,"prevQuarterClose":24.92,"fiveDayClose":19.5606,"twentyDayClose":21.9873},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOC\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666597368","title":"Novo Nordisk’s CagriSema Trial Targets Painful Diabetic Nerve Damage","url":"https://stock-news.laohu8.com/highlight/detail?id=2666597368","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666597368?lang=en_us&edition=fundamental","pubTime":"2026-09-11 00:30","pubTimestamp":1789057833,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The study, officially titled “Efficacy and Safety of co Administered Cagri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisks-cagrisema-trial-targets-painful-diabetic-nerve-damage?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisks-cagrisema-trial-targets-painful-diabetic-nerve-damage?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0154236417.USD","BK4007","LU1093756168.USD","BK4588","NVOC","BK4585","NVO","THNR","NVOH","IE00BKVL7J92.USD","OZEM","PPH","BK4532","LU1093756325.SGD","NVOX","IE00BZ1G4Q59.USD","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666453561","title":"Novo Nordisk's Semaglutide Injection Gets Chinese Approval for MASH Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2666453561","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666453561?lang=en_us&edition=fundamental","pubTime":"2026-09-10 17:35","pubTimestamp":1789032909,"startTime":"0","endTime":"0","summary":"Novo Nordisk  said Thursday that China's National Medical Products Administration has approved its Semaglutide injection to treat metabolic-associated steatohepatitis, according to a Google translation of its Chinese statement.The company said that approval was based on results from its ESSENCE trial, which showed that 63% of patients treated with Semaglutide achieved MASH remission and no worsening of liver fibrosis, compared to 34% in the placebo group.Novo also said that 37% of patients treated with semaglutide demonstrated improvements in liver fibrosis and no worsening of MASH, compared to 22% in the placebo group.Treatment with the Smegglutide injection relieved liver inflammation in some patients and improved the \"scar\" tissue formed after long-term liver damage, the company added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756325.SGD","BK4007","IE00BZ1G4Q59.USD","NVOH","NVOX","NVOC","OZEM","BK4599","PPH","BK4585","IE00BKVL7J92.USD","LU0154236417.USD","LU1093756168.USD","BK4532","NVO","THNR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666534630","title":"Novo Nordisk Advances Oral Semaglutide Trial in Obesity: What Investors Should Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2666534630","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666534630?lang=en_us&edition=fundamental","pubTime":"2026-09-10 00:31","pubTimestamp":1788971502,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Novo Nordisk’s new Phase 3 trial, “Efficacy and Safety of Once Daily Oral ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-advances-oral-semaglutide-trial-in-obesity-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-advances-oral-semaglutide-trial-in-obesity-what-investors-should-watch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BZ1G4Q59.USD","LU0154236417.USD","NVOH","LU1093756168.USD","NVOC","THNR","NVOX","NVO","OZEM","BK4588","IE00BKVL7J92.USD","BK4599","BK4532","BK4007","BK4585","LU1093756325.SGD","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666294531","title":"Novo Nordisk A/S Series B Stock Falls Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2666294531","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666294531?lang=en_us&edition=fundamental","pubTime":"2026-09-10 00:02","pubTimestamp":1788969720,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B dropped 1.1% to DKK288.90 Wednesday on what proved to be an overall unfavorable trading session for the stock market, with the OMX Nordic 40 Index falling 1.1% to 2,686.31.This was the stock's second consecutive day of losses.The company closed DKK121.05 short of its 52-week high of DKK409.95, which the company reached on January 23, 2026.Trading volume was 4,429,973, compared to the 50-day average trading volume of 4,078,075.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154236417.USD","NVOX","THNR","LU1093756325.SGD","OZEM","LU1093756168.USD","BK4599","NVOH","BK4588","BK4532","BK4585","IE00BKVL7J92.USD","PPH","BK4007","NVO","NVOC","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587338","title":"Novo Nordisk Advances DKK 15 Billion Share Buyback, Holding 1% of Capital in Treasury Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587338","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587338?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:49","pubTimestamp":1788950956,"startTime":"0","endTime":"0","summary":"An announcement from Novo Nordisk ( ($NVO) ) is now available. Novo Nordisk has continued executing its previously announced share repurchase progr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-advances-dkk-15-billion-share-buyback-holding-1-of-capital-in-treasury-stock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/novo-nordisk-advances-dkk-15-billion-share-buyback-holding-1-of-capital-in-treasury-stock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756168.USD","BK4585","BK4532","NVOC","IE00BZ1G4Q59.USD","LU1093756325.SGD","NVOH","NVOX","BK4588","THNR","BK4599","NVO","LU0154236417.USD","BK4007","OZEM","IE00BKVL7J92.USD","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131969552","title":"Korean Equities Rally Drives Leveraged ETFs Higher, Top Performer Surges 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131969552","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131969552?lang=en_us&edition=fundamental","pubTime":"2026-09-09 10:56","pubTimestamp":1788922612,"startTime":"0","endTime":"0","summary":"South Korean equities extended their upward momentum on September 9, with the broader market index climbing 2%. The rally was led by major memory chipmakers, fueling sharp gains in Hong Kong-listed...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKHQ","RAM","XC","SKDD","MFEM","SKUU","LU0823413587.USD","VRTL","SPXS","VEXC","03121","RGTX","HYNX","VOO","LU0823397103.USD","NVTX","NBIL","MVV","SPYH","DRAL","TEMX","MMAX","EMXC","XW","SPY","LITG","FEMR","OSSL","SKHZ","IVV","MKOR","NVOX","SPYM","EEMO","BK4581","VRC","SKHU","LU0823397285.USD","DMAX","RGYY","HEEM","SMAX","EWY","BK4585","BBAX","BK4007","SPXL","DRAM","FLKR","NEBX","SKHL","SIMX","VEA","XCEM","EDZ","UPRO","SPXU","BK4504","NBIZ","BBEM","RAMZ","SH","LITC","LU0823413660.USD","XCNY","SSO","LITX","COZX","SK","SKHX","YSPY","SPDN","BK4535","FPA","HIBL","NVTC","LABX","BK4141","RGTC","EQLT","BK4582","NVOH","RGTU","LU1956131251.USD","SPUU","NBIG","LITZ","NBIC","ETNG","STXE","RGTZ","SKHA","EEMV","LITU","NVOC","07709","PEMX","KORU","SPYU","ALA","BK4588","SPYQ","ONTX","KEMX","XXCH","SKHYV","SAA","TEUP","KDEF","SKHY","SKHN","DEXC","SDS","KRWX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666772763","title":"Novo Nordisk A/S Stock (NVO) Closed Down by 3.09% on Sep 8: Facts Behind the Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2666772763","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666772763?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:15","pubTimestamp":1788898536,"startTime":"0","endTime":"0","summary":"• Novo Nordisk halted two late-stage Phase 3 ziltivekimab trials due to futility.\n• Positive STEP Young trial results for semaglutide failed to lift sentiment.\n• Technical indicators show a MACD sell signal and oversold Williams %R.","market":"other","thumbnail":"https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262156826-market-movers-nvo-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","THNR","BK4585","LU1093756325.SGD","NVOC","NVOX","PPH","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4588","BK4532","IE00BKVL7J92.USD","BK4599","NVO","NVOH","OZEM","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666437450","title":"GLP1 Drugs Work for Kids, Says Novo Nordisk. They Could be Another Huge Market.","url":"https://stock-news.laohu8.com/highlight/detail?id=2666437450","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666437450?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:35","pubTimestamp":1788888900,"startTime":"0","endTime":"0","summary":"While the GLP1 weight-loss drugs from Eli Lilly and Novo Nordisk are the drug industry's biggest sellers, they aren't yet approved for one of the globe's most troubling obesity groups: children.Monday","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","NVOX","IE00BKVL7J92.USD","THNR","LU0154236417.USD","BK4007","BK4585","NVOH","OZEM","BK4599","PPH","LU1093756168.USD","BK4532","BK4588","NVO","IE00BZ1G4Q59.USD","NVOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665891373","title":"Update: US Equity Futures Mostly Lower as Traders Assess Rising Oil, Canadian Retaliatory Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2665891373","media":"MT Newswires Live","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665891373?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:55","pubTimestamp":1788872154,"startTime":"0","endTime":"0","summary":"(Updates with economic data, recent oil price movement, world markets' overview and corporate stock movements.)US equity futures were mostly lower pre-bell Tuesday, coming off a three-day weekend as t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HBMX","LU0353189763.USD","SGXZ99366536.SGD","03145","LU0097036916.USD","CGDG","IE00BKVL7J92.USD","LU0077335932.USD","LU0889565833.HKD","LU0528227936.USD","LU2360108059.USD","ASML","LU2506952097.USD","TSMZ","LU1244550577.SGD","FOWF","NVOH","SHLD","AVEM","LU2087625088.SGD","LU2458330243.SGD","IE0002141913.USD","LU2111349929.HKD","LU2324357040.USD","LU0211327993.USD","LU2294711713.HKD","LU0965509101.SGD","BK4591","TTEQ","LU0310799852.SGD","LU1153585028.USD","LU2028103732.USD","EMC","LU1868837565.USD","IE00BZ199S13.USD","LU0861579265.USD","ASIA","IE00BQXX3D17.EUR","BK4550","LU0488056044.USD","ASMZ","LU0345774391.USD","LU0266013472.USD","TEK","LU0267386448.USD","CWI","BK4554","LU0541501648.USD","LU2471134796.USD","LU0124676726.USD","LU2271345857.HKD","IE00B4R5TH58.HKD","LU0689626769.HKD","LU1868837722.USD","LU0359202008.SGD","IE00BD6J9T35.USD","LU0320765489.SGD","LU1093756168.USD","LU2244417387.USD","IE00BJT1NW94.SGD","THNR","IE0004445239.USD","LU0198837287.USD","LU0878004406.USD","LU2211814178.USD","LU2265009873.SGD","DIPR","LU1989771016.USD","LU1989772840.SGD","MISL","LU0208291251.USD","KNOW","LU0642271901.SGD","LU0823434740.USD","IFLR","TSMY","STSM","LU2458330169.SGD","LU1037948897.HKD","UMMA","TSMX","IE0009355771.USD","BK4578","LU2106854487.HKD","LU1803068979.SGD","LU0345770308.USD","LU2237443382.USD","IEFA","LU0225283273.USD","LU0432979614.USD","BK4605","LU2471134952.CNY","LU0572940350.SGD","LU2237443978.SGD","LU0823414478.USD","BLOX","DBEU","LU2133065610.SGD","LU2089284900.SGD","LU0070302665.USD","LU0187121727.USD","IE00BQXX3F31.USD","LU0823414551.USD","LU2543165471.USD","LU0384037296.USD","LU0572939691.SGD","OZEM","NATO","LU1057294990.SGD","LU0320765646.SGD","LU2092937221.SGD","LU2506952170.USD","SG9999001176.SGD","LU0264606111.USD","LU0109392836.USD","LU0143863784.USD","LU2750360997.AUD","LU0719512351.SGD","LU1282649810.SGD","IE00BFXG0V08.USD","LU0154236417.USD","LU0889566641.SGD","LU1548497426.USD","BK4602","BAI","LU0084288322.USD","DBEF","BK4532","LU0114720955.EUR","SPWO","SPTE","WUGI","IE00BZ1G4Q59.USD","LU1508157978.USD","LU1934455863.HKD","IE00BJJMRZ35.SGD","LU1934455194.USD","LU1852331112.SGD","LU0882747503.HKD","LU1162221912.USD","LU2750360641.GBP","LU2506951875.HKD","CGIC","LU2023250504.SGD","LU1934455277.USD","LU0823421333.USD","LU2041044095.USD","LU0823421416.USD","LU1804176565.USD","BK4503","LU0965509010.AUD","LU0082616367.USD","LU0158827781.USD","LU0098860793.USD","LU1023059063.AUD","TSMG","AVXC","LU1791710582.SGD","EPAI","LU2491049909.HKD","LU0359201885.HKD","TSMU","BK4527","LU1720051108.HKD","LU0072462343.USD","TSM","LU0345774631.USD","LU2063271972.USD","LU1267930490.SGD","LU0348723411.USD","IE00BHPRN162.USD","LU0211331839.USD","IE00B3M56506.USD","LU0965509283.SGD","FDTX","LU1048588211.SGD","LU2237443549.SGD","LU0056508442.USD","LU2298321311.HKD","PPA","IE00BYQQ9H92.USD","BK4512","CGNG","LU0289960550.SGD","SMH","ASMH","LU1917777945.USD","LU2249611893.SGD","AVSE","LU2471134523.USD","LU1291159041.SGD","LU1244550221.USD","LU0965508806.USD","LU1267930813.SGD","AIQ","LU2362541273.HKD","LMTS","LU0359201612.USD","IDEF","LU0353189680.USD","LU2237443622.USD","LU1989764748.USD","BK4581","WDGF","PPH","LU0345770993.USD","LU2250418816.HKD","NVO","NVOX","CORO","LU1244550494.USD","LMTL","LU2247934214.USD","LU0823434583.USD","LU1718418525.SGD","PQNT","BK4585","BK4548","LU0823416689.USD","LU1989764664.SGD","CNEQ","LU2125154935.USD","LU1061106388.HKD","ROIV","BK4612","SGXZ51526630.SGD","LU0175139822.USD","SGXZ81514606.USD","ASMG","03165","GSID","LU2471134879.HKD","BSX","BK4082","BK4604","LU0792757196.USD","LU1037948541.HKD","IE0004091025.USD","IE00BQXX3C00.GBP","LU0122379950.USD","LU2112291526.USD","LU0345769631.USD","LU1720051017.SGD","LU2362540622.SGD","ILOW","LU0158827948.USD","LU0211328371.USD","LU2360106780.USD","MEMX","LU2357125470.USD","LU0251132253.USD","SG9999004220.SGD","BK4533","BK4141","LU1974910355.USD","CHPX","TINS","BK4564","LU0323591593.USD","NVOC","LU0823417653.USD","LU2357305700.SGD","LU0541502299.USD","LU1791710400.SGD","ADVE","FENI","IE00B5TLWC47.USD","LU0316494557.USD","BK4526","LU2054465674.USD","SG9999000418.SGD","LU0882574055.USD","LU2491050071.SGD","IE00B2B36J28.USD","LU2663582299.SGD","LU1316542783.SGD","LU2023251221.USD","BK4147","LU1623119135.USD","EFA","IE0004086264.USD","LU0011850046.USD","BK4139","IE00BKPKM429.USD","LU2360032135.SGD","TWSC","BK4534","LU1323610961.USD","BK4007","LU0094547139.USD","SGXZ57979304.SGD","LU1023057109.AUD","CGGO","LU2242649171.HKD","NVS","LU0823417737.USD","BK4504","LU1868838027.USD","BK4516","SG9999013999.USD","PTH","LU0048584097.USD","LU1989772923.USD","LU2362541513.USD","EMM","IE00BFTCPJ56.SGD","LU0238689110.USD","MEDX","LU1734074674.USD","LU0950375773.USD","FFGX","LU1282649067.USD","SG9999001176.USD","BK4599","LU2089283258.USD","LU2860962120.EUR","LU2506951792.HKD","LU1929549753.HKD","ASMU","ESIM","LMT","LU0878005551.USD","LU2125154778.USD","LU2211815571.USD","LU2491050154.USD","LU0138981039.USD","BK4588","LU0345769128.USD","LU1983299246.USD","LU1712237335.SGD","BK4187","LU1093756325.SGD","LU2506951958.HKD","BK4505","LU1366192091.USD","LU0143863198.USD","LU1211504680.USD","BK4543"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665532264","title":"Plastic Surgery is Booming with Boomers. Here's How to Cash in on the Antiaging Craze.","url":"https://stock-news.laohu8.com/highlight/detail?id=2665532264","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665532264?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:58","pubTimestamp":1788865080,"startTime":"0","endTime":"0","summary":"Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgeryBoomers are the suddenly the fastest-growing customers for cosmetic surgery.Baby boomers are the wealthiest ge","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU0912757837.SGD","LU1023059063.AUD","LU0124676726.USD","LU0170899867.USD","BK4534","LU0289739699.SGD","IE000BZT7R73.USD","LU1267930490.SGD","SG9999015986.USD","IE00BVYPNW00.USD","LU0882574055.USD","LU0859254822.USD","LU0310799852.SGD","LU1430594728.SGD","LU1934455277.USD","SG9999015952.SGD","LU0795875086.SGD","LU0511384066.AUD","LU0069063385.USD","LU1057294990.SGD","LU1670628061.USD","LU1162221912.USD","IE00B42XCP33.USD","LU2433249047.HKD","IXJ","LU0234570918.USD","LU0289961442.SGD","LU0661504455.SGD","LU2237443382.USD","LU0289739343.SGD","IE00BVYPNV92.GBP","LU1037948541.HKD","LU1839511570.USD","NVOC","LU0310800379.SGD","LU1923622614.USD","LU2237443622.USD","LU2237443549.SGD","LU2237443978.SGD","LU0726765562.USD","LU1989772923.USD","PJP","LU0943347566.SGD","BK4588","IE00BGHQF631.EUR","LU1291159041.SGD","ESTA","LU0820561909.HKD","LU1551013342.USD","IE000MB6IJN5.SGD","LU2324357040.USD","IE00B4R5TH58.HKD","BK4139","LU0320765646.SGD","IE0009355771.USD","LU0122379950.USD","BK4585","LU1496350502.SGD","LU0395794307.EUR","LU0823416689.USD","LU0868494617.USD","IE00BDGV0183.EUR","LU1934455194.USD","LU2129689431.USD","IE00BBT3K403.USD","LU1732800096.USD","LU0432979614.USD","SG9999003800.SGD","LU1989771016.USD","LU1267930573.SGD","LU1983299246.USD","LU1244550221.USD","LU0949170772.SGD","RXL","THNR","IE00BLSP4452.SGD","LU1236620750.USD","LU1093756325.SGD","LU0689472784.USD","LU0985320562.USD","IE000SO60NU8.SGD","LU1670627923.USD","LU0114720955.EUR","LU2112291526.USD","LU2125909247.SGD","BK4566","LU2089984988.USD","LU0553294199.USD","LU2237443895.HKD","AGNG","LU0417517546.SGD","TRUH","LU0689626769.HKD","LU1236620834.HKD","NVO","SG9999015978.USD","IE00B3PB1722.GBP","LU1718418525.SGD","LU2237443465.HKD","LU2125909593.SGD","LU1585245621.USD","LU0965509283.SGD","LU1037948897.HKD","LU2133065610.SGD","LU1074936037.SGD","LU1732799900.SGD","MEDX","IE000F7OJYX1.SGD","PPH","LU0861579265.USD","LU2129689605.HKD","LU0472753341.HKD","LU1244550494.USD","LU0154236417.USD","BK4007","LU0029864427.USD","LU0203347892.USD","LU0256863811.USD","BK4550","LU0058720904.USD","BK4599","LU0820561818.USD","LU1093756168.USD","OZEM","GLAM","LU0942090050.USD","LU1934455863.HKD","LU0057025933.USD","LU0203345920.USD","BK4581","IE00BSNM7G36.USD","NVOH","GALDY","LU1003077747.HKD","LU2347655073.USD","LU1551013425.SGD","BK4198","LU1989772840.SGD","LU0256863902.USD","IE00BZ1G4Q59.USD","IE0002141913.USD","VHT","LU0098860793.USD","IE00BKVL7J92.USD","IE00BLSP4239.USD","IE0002270589.USD","LU1061106388.HKD","LU0211328371.USD","LU2023251221.USD","BK4559","LU0128525929.USD","LU1244550577.SGD","SG9999011175.SGD","LU2468319806.SGD","LU2357627491.SGD","ABBV","LU2089284900.SGD","LU0708994859.HKD","LU0738911758.USD","BK4532","IE0000B7K699.USD","LU2087621335.USD","IE00BN8TJ469.HKD","IYH","IE000WAW04H5.SGD","LU2347655156.SGD","BK4533","SG9999015945.SGD","IE00BJT1NW94.SGD","LU0965509010.AUD","NVOX","LU0456855351.SGD","LU0795875169.SGD","IE00BFTCPJ56.SGD","LU0545039389.USD","XLV","LU0234572021.USD","LU0965509101.SGD","FTXH","LU2129689514.USD","LU1496350171.SGD","LU0965508806.USD","LU0158827948.USD","FHLC","IE00B19Z3581.USD","SG9999001440.SGD","LU0211327993.USD","LU0868494708.USD","LU1929549753.HKD","LU2089283258.USD","IE0004445239.USD","LU0198837287.USD","IE00B19Z3B42.SGD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665832664","title":"Novo Nordisk Phase 3 Trial Meets Primary Endpoint for Child Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2665832664","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665832664?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:12","pubTimestamp":1788858753,"startTime":"0","endTime":"0","summary":"Novo Nordisk  said Monday its phase 3 Step Young trial evaluating once-weekly semaglutide in children aged six to under 12 with obesity met its primary endpoint.The treatment produced a superior reduction in body mass index at 68 weeks compared with a placebo, the company said.The study also achieved its secondary endpoint for body mass index classification improvement, resulting in 40.4% of treated patients no longer meeting the criteria for obesity, it said.Safety results aligned with previous trials and showed no adverse effects on growth or pubertal development, Novo Nordisk said.Shares of the company were down 1.2% in Tuesday premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVOC","NVO","NVOH","LU0154236417.USD","PPH","THNR","BK4585","OZEM","NVOX","BK4007","LU1093756325.SGD","BK4532","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4588","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665325786","title":"Market Chatter: Novo Nordisk Halts Two More Ziltivekimab Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2665325786","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665325786?lang=en_us&edition=fundamental","pubTime":"2026-09-08 16:57","pubTimestamp":1788857878,"startTime":"0","endTime":"0","summary":"Novo Nordisk  has stopped two additional trials of its experimental cardiovascular drug, ziltivekimab, after an independent committee found a low chance they would produce a different result from an earlier failed study, Reuters reported Monday.The trials, which tested the drug in heart failure patients, will end early, the company told MT Newswires. It added that patients will continue through to their 3-months follow-up as already planned.Novo said its trial testing ziltivekimab in an acute setting following a heart attack will continue as planned with results expected in H1 2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LU0154236417.USD","NVOH","OZEM","NVOX","BK4585","IE00BZ1G4Q59.USD","BK4532","LU1093756168.USD","THNR","IE00BKVL7J92.USD","NVO","PPH","BK4588","LU1093756325.SGD","BK4599","NVOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106138144","title":"The Inflammation Bet Unravels: Novo And Novartis Both Stumble In Cardiovascular","url":"https://stock-news.laohu8.com/highlight/detail?id=1106138144","media":"Bellwether Stocks Movement","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106138144?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:29","pubTimestamp":1788852576,"startTime":"0","endTime":"0","summary":"","market":"fut","thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/1021.webp","type":0,"news_type":0,"thumbnails":["https://news-video-sg.skytigris.cn/videos/covers/1021.webp"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"The Inflammation Bet Unravels: Novo And Novartis Both Stumble In Cardiovascular","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOX","NVS","NVOH","NVO","NVOC"],"isVideo":true,"video":{"duration":72,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/1021/render_1021_1788852029273.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/1021.webp","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/1021/tts/voiceover_9390fdb8b84958e8.mp3","isAI":true},"gpt_icon":0},{"id":"2665328428","title":"Novo Nordisk (0QIU) Receives a Hold from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2665328428","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665328428?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:25","pubTimestamp":1788852330,"startTime":"0","endTime":"0","summary":"Barclays analyst James Gordon CFA maintained a Hold rating on Novo Nordisk today and set a price target of DKK300.00. According to TipRanks, Gordon...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/novo-nordisk-0qiu-receives-a-hold-from-barclays-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/novo-nordisk-0qiu-receives-a-hold-from-barclays-blurbs-news-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVOC","BK4532","NVOX","NVO","NVOH","PPH","IE00BKVL7J92.USD","LU1093756168.USD","LU0154236417.USD","BK4007","OZEM","IE00BZ1G4Q59.USD","LU1093756325.SGD","THNR","BK4585","BK4588","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665631001","title":"Novo Nordisk halts two trials testing ziltivekimab, Bloomberg reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2665631001","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665631001?lang=en_us&edition=fundamental","pubTime":"2026-09-08 05:40","pubTimestamp":1788817216,"startTime":"0","endTime":"0","summary":"Novo Nordisk (NVO) has halted two trials testing if ziltivekimab, its experimental heart disease medicine, would help patients with heart failure, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novo-nordisk-halts-two-trials-testing-ziltivekimab-bloomberg-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novo-nordisk-halts-two-trials-testing-ziltivekimab-bloomberg-reports-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","NVO","LU0154236417.USD","LU1093756168.USD","BK4599","BK4532","BK4588","IE00BKVL7J92.USD","LU1093756325.SGD","THNR","NVOX","NVOH","NVOC","BK4007","OZEM","IE00BZ1G4Q59.USD","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665376683","title":"Yen advances to six-month high, chip stocks rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2665376683","media":"Nicholas Reynolds / Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665376683?lang=en_us&edition=fundamental","pubTime":"2026-09-08 02:14","pubTimestamp":1788804840,"startTime":"0","endTime":"0","summary":"The yen extended Monday's advance to reach the strongest level since February, aided by rising expectations of a Bank of Japan interest-rate increase next week.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"edge_highlight","url":"https://www.theedgesingapore.com/news/highlight/stocks-asia-poised-edge-down-yen-focus?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/news/highlight/stocks-asia-poised-edge-down-yen-focus?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["IE00B19Z3B42.SGD","LU1623119135.USD","LU0868494708.USD","LU2317271919.USD","LU2089283258.USD","LU1032466523.USD","LU1914381329.SGD","LU0345769128.USD","IE00BJTD4N35.SGD","LU0949170772.SGD","IE00BBT3K403.USD","XLF","LU0323591593.USD","LU2237443382.USD","IXG","LU0738911758.USD","BK4528","LU0417517546.SGD","IE00BLSP4452.SGD","LU2357627491.SGD","LU0289739343.SGD","IGV","LU0859254822.USD","LU1280957306.USD","BK4599","IE0034235303.USD","NVOH","TPOR","LU1093756168.USD","LU0868494617.USD","LU2237443549.SGD","IE00BYXW3230.USD","LU0820561818.USD","LU1894683264.USD","LU0198837287.USD","LU2211815571.USD","LU1064131342.USD","LU1116320737.USD","LU0345774391.USD","LU2456880835.USD","ADBE","LU0127658192.USD","LU1935042215.USD","LU1429558221.USD","SG9999015978.USD","LU1989772840.SGD","LU2023250330.USD","IE00BKDWB100.SGD","LU0965509010.AUD","IE00B7SZLL34.SGD","IE00BZ199S13.USD","LU1629891620.HKD","LU2108987350.USD","SG9999011175.SGD","LU0943347566.SGD","LU0511384066.AUD","LU2360107325.USD","BK4505","BK4543","LU1489326972.SGD","LU2552382215.SGD","FDRV","LU2023250843.SGD","LU1803068979.SGD","LU2264538146.SGD","LU1037948897.HKD","LU0068578508.USD","BK4550","LU0861579265.USD","SG9999018857.SGD","LU0476273544.USD","LU0342679015.USD","LU2430703095.HKD","TRUF","LU1852331112.SGD","LU0211328371.USD","BK4535","LU2896262040.SGD","LU0187121727.USD","LU1551013425.SGD","LU0878866978.SGD","LU0211326839.USD","SG9999002224.SGD","LU0234572021.USD","BK4023","ADBG","SORCLmain","LU2023251221.USD","IE00BN8TJ469.HKD","LU0672654240.SGD","LU0289961442.SGD","LU1496350171.SGD","LU2552382132.HKD","LU1934455863.HKD","IE00B5TLWC47.USD","IE00BDRTCR15.USD","LU1720051108.HKD","LU2237443465.HKD","LU2404859741.USD","UYG","LU1244550494.USD","LU1989772923.USD","BK4097","IE00B5949003.HKD","LU1244550221.USD","LU2756315664.SGD","PPH","LU0787776722.HKD","LU0557290698.USD","SG9999014898.SGD","LU1119994496.HKD","LU0965509101.SGD","BK4592","IE00B19Z9505.USD","LU0345769631.USD","LU0081259029.USD","THNR","IE0002270589.USD","ORAC","IE00B19Z3581.USD","LU0320765059.SGD","LU0310799852.SGD","LU1145028129.USD","LU0106261372.USD","LU1316542783.SGD","LU2054465674.USD","IE00BHPRN162.USD","IE00BQXX3C00.GBP","LU0683600562.USD","LU1093756325.SGD","NVO","LU2242649171.HKD","LU2125154778.USD","LU2236285917.USD","IE00BFMHRM44.USD","LU1814569148.SGD","IE00BQXX3F31.USD","LU0882574139.USD","LU0545039389.USD","LU2125154935.USD","IE00BK4W5M84.HKD","BK4230","BK4533","JPM","LU0057025933.USD","LU0689472784.USD","LU1935042488.USD","LU2462157665.USD","SG9999018865.SGD","LU1823568750.SGD","BK4207","SGXZ31699556.SGD","LU0154236417.USD","LU0690374961.EUR","BK4007","BK4566","LU0109391861.USD","LU1861214812.USD","IE00BMPRXR70.SGD","IE00B3S45H60.SGD","ORCS","LU0070302665.USD","BK4585","LU1267930730.SGD","LU0353189763.USD","LU2860962120.EUR","LU0289960550.SGD","LU2417539215.USD","LU0964807845.USD","IE00BYQQ9H92.USD","IE0034235295.USD","LU2357305700.SGD","TFNS","LU0320765489.SGD","LU0157215616.USD","SGXZ51526630.SGD","LU0496365809.HKD","LU1069347547.HKD","LU2543165471.USD","GB00BDT5M118.USD","LU0640476718.USD","LU0553294199.USD","LU0265550946.USD","LU0820562030.AUD","IE00BMPRXN33.USD","BK4532","LU0061474960.USD","LU0211326755.USD","LU2097829019.USD","LU0552385451.USD","BK4503","LU1670628061.USD","LU1496350502.SGD","LU0980610538.SGD","LU1861219969.SGD","LU0238689110.USD","LU0265550359.USD","LU1935043023.USD","LU0345774631.USD","LU1670627923.USD","LU0971096721.USD","BK4536","LU2089284900.SGD","FTXO","LU1917777945.USD","LU0215105999.USD","LU0203347892.USD","LU0976567544.SGD","LU2430703251.USD","LU1037948541.HKD","LU2505996509.AUD","LU0234570918.USD","LU0719512351.SGD","LU0985489474.SGD","LU2168563687.JPY","NVOC","ORCL","LU2244417387.USD","LU0965508806.USD","IE00BK4W5L77.USD","SG9999002232.USD","IE00B775SV38.USD","LU0256863811.USD","BK4588","LU1934455277.USD","IE00BLSP4239.USD","LU1003077747.HKD","LU0109392836.USD","IE0009356076.USD","LU1642822529.SGD","SG9999014880.SGD","LU0082616367.USD","WNDR","LU1935043536.SGD","SG9999003800.SGD","IE00BZ1G4Q59.USD","LU1244550577.SGD","LU2237957811.SGD","SGXZ81514606.USD","LU2210149790.SGD","LU2360106780.USD","LU2458330243.SGD","LU0648001328.SGD","IE00BJTD4V19.USD","IYF","IE00BFXG1179.USD","LU1506573853.SGD","JPO","VFH","LU0345770993.USD","LU0056508442.USD","LU2106854487.HKD","LU1046421795.USD","IE00BJLML261.HKD","LU1720051017.SGD","LU0251132253.USD","LU1712237335.SGD","LU0957808578.USD","LU1366333091.USD","LU1988902786.USD","NVOX","LU2237443895.HKD","SG9999014906.USD","LU1983260115.SGD","LU0170899867.USD","LU1035773651.USD","OZEM","LU2087625088.SGD","LU0149725797.USD","LU0203345920.USD","OGIG","SG9999015952.SGD","LU0965509283.SGD","LU0175139822.USD","LU1633808545.USD","LU1267930490.SGD","LU1435385759.SGD","BK4534","GB00B4QBRK32.GBP","LU0267386448.USD","LU1691799644.USD","BK4516","LU0006306889.USD","LU2023250504.SGD","LU0444971666.USD","IYT","IE00BMPRXQ63.HKD","BK4022","BK4551","LU2458330169.SGD","LU2381873111.SGD","IE000M9KFDE8.USD","ORCZ","LU0661504455.SGD","LU0820561909.HKD","LU0208291251.USD","LU1363072403.SGD","LU2237443622.USD","LU2168564495.EUR","LU0314106906.USD","LU0889566641.SGD","LU2237957902.USD","LU1815333072.USD","LU2746668974.SGD","LU1548497426.USD","LU0708995401.HKD","LU0792757196.USD","LU2168564065.EUR","LU2168564222.USD","IE00BKVL7J92.USD","LU0314104364.USD","LU0353189680.USD","LU2210150020.SGD","LU1934455194.USD","IE00BFXG0V08.USD","LU0256863902.USD","LU0107464264.USD","LU2326559502.SGD","IE00BWXC8680.SGD","SG9999017495.SGD","LU1267930813.SGD","UBEW","IYG","BK4538","BK4527","LU2430703178.SGD","LU0957791311.USD","LU1674673428.USD","LU1116320901.HKD","LU0048584097.USD","LU1894683348.USD","IE00BDCRKT87.USD","LU0106831901.USD","BK4567","LU0444973449.USD","LU1201861249.SGD","LU1261432733.SGD","LU1815336760.USD","LU1668664300.SGD","LU2213496289.HKD","ORCX","IE0034235188.USD","SG9999000418.SGD","LU2095319765.USD","LU2552382058.USD","JPMO","LU1366192091.USD","LU1974910355.USD","LU2250418816.HKD","LU2592432038.USD","SG9999015986.USD","IE00BQXX3D17.EUR","LU1551013342.USD","LU2237443978.SGD","LU1989764748.USD","LU1084165304.USD","LU0069063385.USD","LU0472753341.HKD","SG9999015945.SGD","LU2746668461.USD","LU1935042991.SGD","LU0348723411.USD","LU0320765646.SGD","IE00B1XK9C88.USD","LU2168564149.EUR","LU1235294995.USD","LU2756315318.SGD","IE00B1BXHZ80.USD","LU0345770308.USD","LU0158827948.USD","LU0690374615.EUR","FNCL","LU2237438978.USD","LU0433182093.SGD","UBER","KBWB","SGXZ99366536.SGD","ORCU","LU1989764664.SGD","BK4554","LU1778281490.HKD","UBRL","TDIV","LU0210536198.USD","BK4581","LU2505996681.GBP","LU1674673691.USD","LU0642271901.SGD","ADBU","LU0889565833.HKD","SG9999001424.SGD","BK4504","IE0004445239.USD","LU0942090050.USD","GB00B4LPDJ14.GBP","LU2360032135.SGD","LU0211331839.USD","LU1162221912.USD","SG9999014914.USD","LU0211327993.USD","LU2404859667.USD","LU0130102774.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665109773","title":"Novo Nordisk announces STEP Young phase 3 trial met its primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2665109773","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665109773?lang=en_us&edition=fundamental","pubTime":"2026-09-08 02:10","pubTimestamp":1788804610,"startTime":"0","endTime":"0","summary":"Novo Nordisk (NVO) announced first results from the STEP Young phase 3 trial, evaluating once-weekly semaglutide in combination with a reduced-calo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novo-nordisk-announces-step-young-phase-3-trial-met-its-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novo-nordisk-announces-step-young-phase-3-trial-met-its-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4599","BK4532","BK4588","LU0154236417.USD","BK4007","NVOX","LU1093756325.SGD","IE00BKVL7J92.USD","NVOH","IE00BZ1G4Q59.USD","PPH","NVOC","BK4585","THNR","OZEM","LU1093756168.USD","NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665862310","title":"Novo Nordisk (NVO) Hit by Another Heart Drug Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2665862310","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665862310?lang=en_us&edition=fundamental","pubTime":"2026-09-08 00:56","pubTimestamp":1788800218,"startTime":"0","endTime":"0","summary":"Novo Nordisk ($NVO) has halted two late‑stage studies of its experimental heart drug ziltivekimab, marking a major setback in its push into cardiov...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/novo-nordisk-nvo-hit-by-another-heart-drug-setback?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/novo-nordisk-nvo-hit-by-another-heart-drug-setback?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPH","BK4599","IE00BZ1G4Q59.USD","NVO","IE00BKVL7J92.USD","BK4532","BK4585","LU1093756325.SGD","NVOH","THNR","LU1093756168.USD","LU0154236417.USD","BK4007","NVOC","OZEM","NVOX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665731749","title":"Novo Nordisk A/S Series B Stock Flat Monday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2665731749","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665731749?lang=en_us&edition=fundamental","pubTime":"2026-09-08 00:02","pubTimestamp":1788796920,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novo Nordisk A/S Series B were flat  at DKK298.95 Monday on what proved to be an overall positive trading session for the stock market, with the OMX Nordic 40 Index rising 0.3% to 2,710.84.The stock's rise  snapped a two-day losing streak.The company closed DKK111.00 short of its 52-week high of DKK409.95, which the company reached on January 23, 2026.Trading volume was 1,797,150, compared to the 50-day average trading volume of 4,122,224.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","NVO","OZEM","BK4007","BK4532","IE00BKVL7J92.USD","NVOX","NVOC","BK4585","NVOH","BK4588","LU0154236417.USD","LU1093756325.SGD","PPH","BK4599","IE00BZ1G4Q59.USD","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665131175","title":"Novo Nordisk Stock (NVO) Falls Despite Success in Children’s Weight-Loss Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665131175","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665131175?lang=en_us&edition=fundamental","pubTime":"2026-09-07 20:32","pubTimestamp":1788784376,"startTime":"0","endTime":"0","summary":"Novo Nordisk’s ($NVO) shares in Copenhagen edged lower on Monday afternoon. This came even after the Danish pharma giant said in a statement that i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/novo-nordisk-stock-nvo-falls-despite-success-in-childrens-weight-loss-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/novo-nordisk-stock-nvo-falls-despite-success-in-childrens-weight-loss-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756168.USD","NVOC","LU0154236417.USD","NVOH","NVOX","OZEM","IE00BKVL7J92.USD","BK4599","PPH","BK4585","LU1093756325.SGD","BK4588","IE00BZ1G4Q59.USD","THNR","BK4532","NVO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":112,"code":"91000000","status":"200"}]}}